Hemolytic anemia cost-effectiveness of therapy

Jump to navigation Jump to search

Authors: Shyam Patel [1]

Hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT Scan

MRI Scan

Echocardiography or Ultrasound

Imaging Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic anemia cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic anemia cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic anemia cost-effectiveness of therapy

CDC on Hemolytic anemia cost-effectiveness of therapy

Hemolytic anemia cost-effectiveness of therapy in the news

Blogs on Hemolytic anemia cost-effectiveness of therapy

Directions to Hospitals Treating Hemolytic anemia

Risk calculators and risk factors for Hemolytic anemia cost-effectiveness of therapy

The most cost-effective intervention for workup of hemolytic anemia is labs including a complete blood count and physican exam.

The most cost-effective intervention for therapy of hemolytic anemia is corticosteroids. Alternative immunosuppressive agents like cyclosporine or azathioprine are more costly and should only be used if corticosteroids are ineffective or cannot be tolerated.


References